• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Wednesday 06/28/2017
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Medical

  • 3:22 PM

    NEW YORK, NY–DEWM, (Marketwired – Jun 26, 2017) – Dewmar International BMC, Inc. (OTC PINK: DEWM), a diversified brand management and operating company that conducts business across variegated business sectors, announced its Profit Reinvestment Program™ (PREP) which was formed in 2015 to earmark up to $4,000,000 in retained earnings towards a series of synergistic business opportunities with the objective of creating diversified revenue streams for the Company. PREP™ Investments focused primarily on three sectors; these are: (1) Healthcare Services/Technologies (2)

    Read more
  • 10:11 PM

      Viratech has successfully integrated and delivered to the Cancer.im. Social Network, an Approved Apple IOS Application for iPhones and iPads RENO NV – Viratech Corp. (the “Company”) (OTC PINK: VIRA) is an open source mobile & social knowledge networking technology company, focused on creating Social Network Application Platforms (SNAPs), specifically, social network driven wikis, harnessing social collaboration in a way to give the user a more in depth perspective of a researched subject or action, announced today that it

    Read more
  • 10:06 PM

    The Robert Ryan Cancer Protocol is based on the pioneeering work of Dr. Nicos Nikolau, who in October of 2007 published a study titled “Quality of Life (QOL) Supersedes the Classic Predictors of Survival in Locally Advanced Non Small Cell Lung Cancer”  This Rosetta Stone study was the first time that a qualiatitve measure (Quality of Life) was validated in an evidenced based medicine study to have validated medical benefit. Leveraging the EORTC (European Organization for the Research and Treatment of

    Read more
  • 10:40 AM

    The Company may be the first to offer an all-natural ‘cancer cocktail’ combining the therapeutic benefits of the plant and animal kingdoms PR Newswire, PTLF HANCOCK, Maryland, June 14, 2017 HANCOCK, Maryland, June 14, 2017 /PRNewswire/ — PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, reports on its solution to the ever increasing problem of drug resistance and high toxicity in the treatment of cancer in

    Read more
  • 7:14 AM

    NORTHVALE, N.J., May 31, 2017, ELTP, (GLOBE NEWSWIRE) — Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB:ELTP) announced today the issuance of European Patent No. 1615623 titled “Abuse-Resistant Oral Dosage Forms and Method of Use Thereof” issued March 22, 2017. This patent expands the intellectual property for the Company’s opioid abuse deterrent technology. Elite now has four US patents, one European patent, and two Canadian patents issued in this area with additional patents pending in the U.S., Canada and Europe.

    Read more
  • 9:00 AM

    VANCOUVER, Washington, May 17, 2017, CYDY, (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, announces the treatment of the first patient in its Phase 2 clinical trial for Graft versus Host Disease (GvHD), its leading immunologic indication for PRO 140. GvHD is a potentially life-threatening complication in patients requiring a bone marrow transplant because their immune systems have been depleted during aggressive cancer therapy for

    Read more
Public Wire Banner